Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc. - Chair of Scientific Advisory Board Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world. He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent.
Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.
Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.
Allen A. Herman, M.B., Ch.B., Ph.D. Dr. Allen Herman is an epidemiologist and public health physician. He was the founding Dean of the National School of Public Health, Medical University of Southern Africa of the Republic of South Africa. He graduated in Medicine from the University of Natal in 1977 and completed his doctoral work in Epidemiology at the University of the Witwatersrand in 1989. He was a postdoctoral fellow in Epidemiology at Columbia University in New York in 1986 and a member of the faculty from 1987 to 1988. From 1989 to 1997 he was a Visiting Scientist at the National Institutes of Health. He was an Adjunct Professor at the George Washington University School of Public Health and Health Services from 1997 to 2004. Dr. Herman has extensive experience in developing and managing epidemiologic and public health research projects, and he is adept at secondary data analysis. In 1990 he helped develop the Baltimore Project, an Infant Mortality Reduction Initiative in Baltimore, Maryland. This community-based, model enriched prenatal care demonstration project for East Baltimore formed part of the basis for a $160 million dollar federally funded national program to reduce infant mortality. In 1992 he developed the scientific basis of the National Institutes of Health - District of Columbia Infant Mortality Reduction Initiative. He was the scientific director of this $25 million community-based U.S. federal research project that was designed to identify the critical factors that contribute to a high infant mortality among poor inner city African Americans and to develop interventions to reduce infant mortality rates.
Dr. Herman was effective in harnessing the energies of South Africans and Americans to fight HIV/AIDS in Africa. He led the development of the Bristol-Myers Squibb Company Secure the Future Project, a $100 million program that focused on the health of women and children infected and affected by HIV. He was the Advisor to then Chairman Ronald V. Dellums, who served President Bill Clinton (during his second term) as the Chairman of the U.S. Presidential Committee on HIV/AIDS on HIV/AIDS in Africa. Dr. Herman, Mr. Dellums and Congresswoman Barbara Lee (the founding cochair of the Congressional HIV/AIDS Caucus) developed the idea of an “AIDS Marshall Plan for Africa” which was transformed into the Global Fund to fight AIDS, Tuberculosis and Malaria, which led in 2003 to the President’s Emergency Plan for AIDS Relief (PEPFAR) and its reauthorization in 2008. Dr. Herman was the director of the Secure the Future Public Health Fellowship Program that trained more than 150 fellows in dealing with AIDS. This is the largest such training program in Africa, and his students included the Minister of Health of Swaziland, the Director of the AIDS Program of Lesotho, and the Directors of the AIDS Programs from a number of South African provinces. He also worked as the advisor to the South African National Defense Force and helped bring a substantial antiretroviral treatment program to the South African military. This program was designed to bring treatment through the use of clinical trials to a large population of military families and was designed to enable the South African government to objectively create programs of treatment for the large number of infected South Africans. For his work in HIV/AIDS, Dr. Herman was awarded the Heroes in Medicine award by the International Association of Physicians in AIDS Care.
Click here to read Dr. Herman's Curriculum Vitae
Dorothy Bray, Ph.D.- Senior Clinical Development Consultant Dr. Dorothy Bray, Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Ronald V. Dellums A life-long advocate of peace and social justice, Ron Dellums served for 27 years as an outspoken and highly respected member of the US House of Representatives. Initially seeking a life in education, community activism and social work, Mr. Dellums was called to public office in 1967. His tenure in politics has been defined by a strong adherence to the principles of social justice, community activism and peace as viable and necessary national and international pursuits. In 2007, Mr. Dellums returned to public office as the Mayor of Oakland, California.
Born in Oakland, Mr. Dellums served in the United States Marine Corps, before going on to earn an AA from Oakland City College, a BA from San Francisco State University, and a MSW in psychiatric social work from the University of California, Berkeley. After completing his degrees, Mr. Dellums worked as a psychiatric social worker and in various anti-poverty programs. He served on the Berkeley City Council from 1967 until 1970. He then went on to win a seat to the US Congress, serving from 1971 until 1998.
Throughout his career, Mr. Dellums has brought parties together, removed obstacles, and gotten things done. He has advised world leaders on sensitive matters of global peace and national security in the Middle East, Cuba, South Africa, Haiti, and Bosnia, achieving important outcomes for the international community. At a local level, when the Port of Oakland dredging was stalled, he brought the parties together and found solutions acceptable to the previously warring interests of the Port, the environmental community, labor, and the Corps of Engineers. Similarly, Mr. Dellums was instrumental in resolving countless labor disputes, including an intractable garbage dispute between Waste Management and the Teamsters, as well as a threatened strike of 1,000 Port truck drivers.
Mr. Dellums is currently the President of The Dellums Institute: Partners for Global Health and Justice, an “action tank” to train the new generation of social justice leaders and convene non-traditional partners to work together on tackling major world problems of climate change, youth disenfranchisement, health disparities, and poverty. He also serves as Chair of the Dellums Commission on the Status of Boys and Men of Color, reconvened by the National Collaborative on Health Equity.
Click here to read biography
Harold C. Smith, Ph.D. Dr. Harold C. Smith, Ph.D., Professor in Biochemistry, Biophysics, and Oncology with secondary appointments as Professor in the Department of Genetics and Pathology and a Member of the Center for RNA Biology at the University of Rochester, School of Dentistry and Medicine, to the Company's Scientific Advisory Board. At the University of Rochester Dr. Smith directs a research laboratory and teaches undergraduate and medical school courses in biochemistry. He is a member of the RNA Society and a member of the American Association for the Advancement of Science. He received the SUNY at Buffalo's Distinguished Alumni Award as well as several awards from the University or Rochester for contributions to the teaching mission and leadership in mentoring. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith has also been the recipient of a number of grants, including grants from the Bill and Melinda Gates Foundation, the NIH, the United States Air Force, and the Office of Naval Research. In total, Dr. Smith has received federal and foundation research grants in excess of $6.5 million. Dr. Smith has been an opinion leader in RNA biology where he established the first Gordon Research conference on RNA Editing. Dr. Smith is the author of more than 100 peer-reviewed manuscripts and reviews during his career, exceeding more than 9,973 citations.
Dr. Smith received his Ph.D. from SUNY at Buffalo, following BS and MS degrees from Purdue University and an MA degree from SUNY at Buffalo. Dr. Smith also held post-doctoral positions in biochemistry at SUNY at Buffalo followed by three post-doctoral positions in biochemistry, pharmacology, and medical genetics, respectively, at Baylor College of Medicine.
In addition, Dr. Smith is the Founder and CEO of OyaGen, Inc., a biotech company in Rochester, New York developing novel therapeutics for infectious disease and cancer. OyaGen has raised in excess of $4 million from venture and angel investor sources and two federal grants for assay development.
Dr. Michael J. Goldblatt Dr. Goldblatt, the Former Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), holds extensive experience in successfully pioneering next-generation technologies, including host-oriented therapeutics for infectious disease. He received his B.A. in Biology from Reed College and his Ph.D. and J.D. from the University of California-Davis and is admitted to practice law in New York and Washington, D.C. and with the United States Patent Bar.
Dr. Goldblatt is also the President and CEO of Functional Genetics, a privately held biotechnology Company founded in 2001. Functional Genetics focuses on the development of new antibody-based therapeutics to prevent and treat a broad spectrum of viruses including HIV, Herpes, and respiratory illnesses. Functional Genetics' leading candidate FGI-101-1A6 is a fully human monoclonal antibody which targets and eliminates cells that have been infected by various viruses including HIV-1 and influenza. FGI-101-1A6 has successfully completed its Phase IA clinical trial.
Dr. Goldblatt has over 20 years of experience working in biotechnology, product development, and regulatory affairs. He served as the Science and Technology Officer at McDonald's Corporation and Director of Scientific and Regulatory Affairs at General Foods Corporation. Dr. Goldblatt has extensive knowledge and experience in the identification and commercial development of early stage technologies.
Richard Ogden, Ph.D. Dr. Ogden co-founded RORR Inc., a medical, scientific consulting and education company contracted by U.S. and European-based clients, including the International AIDS Society. RORR provides consulting for companies with a focus on viral infectious disease including HIV, Hepatitis C and respiratory viruses.
Beginning his prestigious career as a Post Graduate Chemist at Cambridge University, Dr. Ogden then held several positions at Agouron Pharmaceuticals including Principal Scientist/Manager, New Projects Research, and Director and Senior Director of Scientific Development. Dr. Ogden was also the Senior Director of Scientific Affairs, HIV US Medical at Pfizer Inc.
Dr. Ogden was a team member in the HIV project that led to the discovery and development of Nelfinavir (Viracept).
In working with Pfizer, he had an additional opportunity to work with the Pfizer Foundation in its support of the Academic Alliance and its efforts in Uganda, and with Corporate Philanthropy, in its support of the World Economic Forum and the Global Business Council.
Dr. Ogden received his bachelor's degree in natural sciences and doctorate in synthetic organic chemistry at Cambridge University. His academic career started with postdoctoral research studying RNA transcription and processing at the University of California, San Diego, following which he undertook independent research, funded by the National Science Foundation, in the area of protein and RNA structure-function relationships at the University of California, San Diego and the Agouron Institute.
Dr. J. Thomas August Dr. August’s distinguished career in clinical research directed at the molecular biology and protein structure of RNA viruses, and clinical exploration of human immunology has positioned him as a leading authority on human immune response mechanisms.
Dr. August currently holds the positions of a University Distinguished Service Professor of Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine, Professor of Medicine, National University of Singapore; and Professor, Perdana University Graduate School of Medicine, Malaysia.
Dr. August has been involved with the development of a new generation of HIV vaccines and the protein antigenic structure of leading viral pathogens, including HIV-1, influenza, and other pathogens including dengue and West Nile viruses. His numerous publications are reflective of scientific commercial enterprises in cancer and HIV.
Dr. Ritchard L. Fishman Dr. Fishman established his practice in 1961, and since then has been seeing patients of all ages for Diabetes, Hypertension, Weight Loss, Arthritis, Pain Management and many other medical problems. Dr. Fishman is widely recognized as a leader in the research in these fields. Since 1998, Dr. Fishman has been involved in clinical trials for medications, treatments, devices and vaccines for major pharmaceutical companies seeking FDA approval. Dr. Fishman is also a Chairman of the New Life Diabetes Center’s Medical Review Board and is responsible for reviewing all medical operations supervised by this Center. Dr. Fishman graduated Ohio State University in 1953 where he earned a Bachelor of Science degree with a Major in Biology. He also received his Medical Doctor degree from Ohio State University in 1957. Dr. Fishman has professional affiliations with the Downey Community Hospital, Whittier Presbyterian Hospital, and Whittier Hospital. Also, he has been a guest lecturer with the Western University School of Osteopathic Medicine and Senior Medical advisor for New Life Diabetic Centers in California and Nevada.
Michael McGrath, MD, Ph.D. Dr. Michael McGrath is co-founder of Pathologica LLC and Neuraltus Pharmaceuticals, both privately held companies involved in developing therapeutic approaches for the treatment of various chronic diseases. Pathologica is developing a novel approach to the treatment of HIV disease, its lead drug candidate, PA-300, targeting HIV reservoirs in macrophages implicated as a cause of HIV related neurologic disease, cardiovascular disease and various forms of cancer. UCSF and Pathologica received approximately $10M from the NIH to perform all of the preclinical studies required by the FDA for administering PA300 to humans, with clinical trials targeted to begin in 2013. Dr. McGrath and colleagues raised $17M in 2009 to fund Neuraltus' phase 2 clinical trial in patients with amyotrophic lateral sclerosis using NP001 in early 2013, the first macrophage targeted approach for Lou Gehrig's disease.
Dr. McGrath maintains an extensive resume spanning more than three decades with a strong focus on HIV and oncology. Dr. McGrath's career in HIV began early in the HIV epidemic as Assistant Professor of Medicine, AIDS/Oncology Division, University of California, San Francisco/San Francisco General Hospital in 1985. In the same year he began serving as an ad hoc grant reviewer for the NIMH, NCI, NIAID and the VA and joined the Scientific Advisory Board for The American Foundation for AIDS Research (AmFAR) where he continues to serve.
Since joining the staff of the UCSF in 1985, Dr. McGrath has held numerous positions at USCF including Assistant Professor of Laboratory Medicine UCSF/SFGH, Associate Professor of Laboratory Medicine and Medicine UCSF/SFGH and Associate Professor of Pathology UCSF/SFGH.
Dr. McGrath earned his Bachelor's of Science (BS) at the University of Minnesota in 1974 in Biology. He obtained his Medical degree (MD) in 1980 at Stanford University School of Medicine and his PhD in Cancer Biology in 1985 at Stanford University School of Medicine.
Robert Melamede, Ph.D. - Cannabis Science President Emeritus Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Scientific Advisory Board of Americans for Safe Access, the Unconventional Foundation for Autism, The World Aids Institute, Board Tim Brown Foundation (The Berlin Patient), Phoenix Tears Foundation, and regularly consults with professional and lay persons around the world regarding cannabis and health issues. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.
News 
Market Data 
Discover 
